한글목차

NOURIANZ는 크산틴 유도체 구조를 가진 이스트라데필린을 함유하고 있습니다. 화학명은 (E)-8-(3, 4-dimethoxystyryl)-1, 3-diethyl-7-methyl-3, 7-dihydro-1H-purine-2, 6-dione, 분자식은 C20H24N4O4입니다.

권장 용량은 1일 1회 20mg 경구 복용이며, 1일 1회 최대 40mg까지 증량할 수 있습니다. 식사와 관계없이 복용할 수 있습니다. 간 손상 환자 중등도 간 손상 환자의 권장 최대 용량은 1일 1회 20mg이며, 중증 간 손상 환자에서는 NOURIANZ 사용을 피해야 합니다. 또한 하루 20개비 이상(또는 이에 상응하는 다른 담배 제품)을 피우는 환자에게는 1일 1회 40mg을 투여하는 것이 권장됩니다.

이 보고서는 주요 7개국의 파킨슨병 치료제 NOURIANZ 시장에 대해 조사했으며, 시장 개요, 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.

목차

제1장 보고서 서론

제2장 파킨슨병에서의 NOURIANZ 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 규제 마일스톤
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신흥 치료법)

제5장 NOURIANZ 시장 평가

• 파킨슨병용 NOURIANZ 시장 전망
• 미국 및 일본 분석
  • 미국 및 일본의 파킨슨병 치료제 NOURIANZ 시장 규모
• 국가별 시장 분석
  • 미국
  • 일본

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight에 대해

제12장 보고서 구입 옵션

영문목차

"NOURIANZ Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about NOURIANZ for Parkinson's disease in the US and Japan. A detailed picture of the NOURIANZ for Parkinson's disease in the United States and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the NOURIANZ for Parkinson's disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the NOURIANZ market forecast analysis for Parkinson's disease in the US and Japan, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.

Drug Summary:

NOURIANZ contains istradefylline, which has a xanthine derivative structure. The chemical name is (E)-8-(3, 4-dimethoxystyryl)-1, 3-diethyl-7-methyl-3, 7￢dihydro-1H-purine-2, 6-dione. Its molecular formula is C20H24N4O4.

Indication

NOURIANZ is indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease experiencing "off" episodes.

Dosage and administration

• The recommended dosage is 20 mg orally once daily, and the dosage may be increased to a maximum of 40 mg once daily.
• It may be taken with or without food.
• In patients with hepatic impairment: The maximum recommended dosage with moderate hepatic impairment is 20 mg once daily and the use of NOURIANZ in patients with severe hepatic impairment should be avoided.
• For patients who smoke 20 or more cigarettes per day (or the equivalent of another tobacco product), the recommended dosage is 40 mg once daily.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the NOURIANZ description, mechanism of action, dosage and administration, research and development activities in Parkinson's disease.
• Elaborated details on NOURIANZ regulatory milestones and other development activities have been provided in this report.
• The report also highlights the NOURIANZ research and development activities in Parkinson's disease across the United States and Japan.
• The report also covers the patents information with expiry timeline around NOURIANZ.
• The report contains forecasted sales of NOURIANZ for Parkinson's disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Parkinson's disease.
• The report also features the SWOT analysis with analyst views for NOURIANZ in Parkinson's disease.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

NOURIANZ Analytical Perspective by DelveInsight

• In-depth NOURIANZ Market Assessment

This report provides a detailed market assessment of NOURIANZ for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• NOURIANZ Clinical Assessment

The report provides the clinical trials information of NOURIANZ for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence NOURIANZ dominance.
• Other emerging products for Parkinson's disease are expected to give tough market competition to NOURIANZ and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of NOURIANZ in Parkinson's disease.
• Our in-depth analysis of the forecasted sales data of NOURIANZ from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the NOURIANZ in Parkinson's disease.

Key Questions:

• What is the product type, route of administration and mechanism of action of NOURIANZ?
• What is the clinical trial status of the study related to NOURIANZ in Parkinson's disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the NOURIANZ development?
• What are the key designations that have been granted to NOURIANZ for Parkinson's disease?
• What is the forecasted market scenario of NOURIANZ for Parkinson's disease?
• What are the forecasted sales of NOURIANZ in the United States and Japan?
• What are the other emerging products available and how are these giving competition to NOURIANZ for Parkinson's disease?
• Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?

Table of Contents

1. Report Introduction

2. NOURIANZ Overview in Parkinson's disease

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and Efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. NOURIANZ Market Assessment

• 5.1. Market Outlook of NOURIANZ in Parkinson's disease
• 5.2. The US and Japan Analysis
  • 5.2.1. Market Size of NOURIANZ in the US and Japan for Parkinson's disease
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of NOURIANZ in the United States for Parkinson's disease
  • 5.3.2. Market Size of NOURIANZ in Japan for Parkinson's disease

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options